Ten-year analysis of the efficacy of vaccination against pneumococcal infection in patients with chronic obstructive pulmonary disease

Major problems in the course of chronic obstructive pulmonary disease (COPD) include frequent exacerbations and related deaths. The use of pneumococcal vaccines, primarily a 13-valent polysaccharide conjugate vaccine, is a generally recognized tool for reducing the number of exacerbations.

The aim of the study was to analyze the prospective clinical efficacy of vaccine prophylaxis with conjugated pneumococcal vaccine Prevenar-13 (PCV13) in patients with COPD over 10 years.

Methods. A total of 362 male patients who were treated or monitored at the Regional Pulmonological Center of Chelyabinsk in 2012 – 2022 were enrolled in the study. The main efficacy endpoints of observation over 10 years were: the dynamics of dyspnea (mMRC score), forced expiratory volume in 1st second, the number of exacerbations, hospitalizations, the number of pneumonias. After confirming the diagnosis of COPD, the patients were divided into two observation groups. The first group (n = 150) included patients vaccinated with PCV13. The second group (n = 212) included patients with COPD who had not received pneumococcal vaccination for various reasons.

Results. Severe forms of the disease and frequent exacerbations predominated in both groups. 96 (27%) deaths were recorded in the PCV13-vaccinated group, and 171 (47%) deaths in the unvaccinated group. The difference between vaccinated and unvaccinated is statistically significant (p < 0.05). In the unvaccinated patients, there was a steady progression of shortness of breath with an increase by 12% compared to baseline (p < 0.05) by the 10^th year. A positive trend in FEV1 was noted in patients vaccinated with PCV13. They also showed a significant decrease in BODE prognostic index.

Conclusion. The use of PCV13 allows for stabilization of the main clinical and functional indicators of the respiratory system in patients with COPD in the long term (at least 10 years of follow-up). Vaccination maintains a low risk of adverse events according to the BODE index; an increase in patient survival was noted over a 10-year horizon (odds ratio – 2.35; 95% confidence interval – 1.45; 3.77), including cases with acute viral damage with COVID-19 (COronaVIrus Disease 2019).

1. Richie R.C. Morbidity and mortality associated with chronic obstructive pulmonary disease (COPD). J. Insur. Med. 2023; 49 (4): 230–243. DOI: 10.17849/insm-49-04-230-243.1.

2. Global Initiative Lung Disease. Global Strategy for Prevention, Diagnosis and Management of Chronic Obstructive Lung Disease: 2023 Report. Available at: https://goldcopd.org/2023-gold-report-2/ [Accessed: September 02, 2023]

3. Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. [Federal guidelines on diagnosis and treatment of chronic obstructive pulmonary disease]. Pul'monologiya. 2022; 32 (3): 356–392. DOI: 10.18093/0869-0189-2022-32-3-356-392 (in Russian).

4. Avdeev S.N. [Is it possible to improve prognosis in patients with chronic obstructive pulmonary disease?] Pul'monologiya. 2015; 25 (4): 469–476. DOI: 10.18093/0869-0189-2015-25-4-469-476 (in Russian).

5. Soler-Cataluna J.J., Martinez-Garcia M.A., Román Sánchez P. et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60 (1): 925–931. DOI: 10.1136/thx.2005.040527.

6. Almagro P., Calbo E., Ochoa de Echaguen A. et al. Mortality after hospitalization for COPD. Chest. 2002; 121 (5): 1441–1448. DOI: 10.1378/chest.121.5.1441.

7. Viniol C., Vogelmeier C.F. Exacerbations of COPD. Eur. Respir. Rev. 2018; 27 (147): 170103. DOI: 10.1183/16000617.0103-2017.

8. Froes F., Roche N., Blasi F. Pneumococcal vaccination and chronic respiratory diseases. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 3457–3468. DOI: 10.2147/copd.s140378.

9. Ignatova G.L., Avdeev S.N., Antonov V.N. Comparative effectiveness of pneumococcal vaccination with PPV23 and PCV13 in COPD patients over a 5-year follow-up cohort study. Sci. Rep. 2021; 11 (1): 15948. DOI: 10.1038/s41598-021-95129-w.

10. Torres A., Blasi F., Dartois N., Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015; 70 (10): 984–989. DOI: 10.1136/thoraxjnl-2015-206780.

11. Jackson M.L., Nelson J.C., Jackson L.A. Risk factors for community-acquired pneumonia in immunocompetent seniors. J. Am. Geriatr. Soc. 2009; 57 (5): 882–888. DOI: 10.1111/j.1532-5415.2009.02223.x.

12. Juthani-Mehta M., De Rekeneire N., Allore H. et al. Modifiable risk factors for pneumonia requiring hospitalization of community-dwelling older adults: the health, aging, and body composition study. J. Am. Geriatr. Soc. 2013; 61 (7): 1111–1118. DOI: 10.1111/jgs.12325.

13. Choi K.Y., Lee H.J., Lee J.K et al. Rapid FEV1/FVC decline is related with incidence of obstructive lung disease and mortality in general population. J. Korean Med. Sci. 2023; 38 (1): e4. DOI: 10.3346/jkms.2023.38.e4.

14. Li Y., Zhang R., Shan H. et al. FVC/DLCO identifies pulmonary hypertension and predicts 5-year all-cause mortality in patients with COPD. Eur. J. Med. Res. 2023; 28 (1): 174. DOI: 10.1186/s40001-023-01130-6.

15. Bustamante-Fermosel A., De Miguel-Yanes J.M., Duffort-Falcó M., Muñoz J. Mortality-related factors after hospitalization for acute exacerbation of chronic obstructive pulmonary disease: the burden of clinical features. Am. J. Emerg. Med. 2007; 25 (5): 515–522. DOI: 10.1016/j.ajem.2006.09.014.

16. [Global Initiative Lung Disease. Global Strategy for Prevention, Diagnosis and Management of Chronic Obstructive Lung Disease. Revised 2011]. Translation from English edited by A.S.Belevsky. Moscow: Russian Respiratory Society; 2012. Available at: https://www.volgmed.ru/uploads/files/2013-3/17409-globalnaya_strategiya_diagnostiki_lecheniya_i_profilaktiki_hronicheskoj_obstruktivnoj_bolezni_lyogkih_2011_gold.pdf?ysclid=lmt6xa50iz356890805 [Accessed: September 02, 2023] (in Russian).

17. Gough J. Discussion on the diagnosis of pulmonary emphysema. J. Proc. R. Soc. Med. 1952; 45 (9): 576–586. DOI: 10.1177/003591575204500902.

18. Froes F., Roche N., Blasi F. Pneumococcal vaccination and chronic respiratory diseases. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 3457–3468. DOI: 10.2147/COPD.S140378.

19. Ignatova G.L., Antonov V.N. [Systemic inflammatory markers as predictors of cardiac complications in patients with comorbid course of chronic obstructive pulmonary disease and ischemic heart disease]. Consilium Medicum. 2018; 20 (11): 40–44. DOI: 10.26442/20751753.2018.11.000042 (in Russian).

20. Singh D., Mathioudakis A.G., Higham A. Chronic obstructive pulmonary disease and COVID-19: interrelationships. Curr. Opin. Pulm. Med. 2022; 28 (2): 76–83. DOI: 10.1097/MCP.0000000000000834.

21. Huang B.Z., Chen Z., Sidell M.A. et al. Asthma disease status, COPD, and COVID-19 severity in a large multiethnic population. J. Allergy Clin. Immunol. Pract. 2021; 9 (10): 3621–3628.e2. DOI: 10.1016/j.jaip.2021.07.030.

22. Halpin D.M.G., Vogelmeier C.F., Agusti A. COVID-19 and COPD: lessons beyond the pandemic. Am. J. Physiol. Lung Cell. Mol. Physiol. 2021; 321 (5): L978–982. DOI: 10.1152/ajplung.00386.2021.